Defense Labs Yield Ideas For U.K. Firms

LONDON—Britain is using “ferrets” to transfer technology from its national defense research laboratories into the civil sector. These two-legged ferrets, all of whom have good technical qualifications, are employed by a technology broker to spot promising ideas and obtain licenses for them. The broker is a private company called Defence Technology Enterprises based at Milton Keynes. Owned by eight British financial institutions, it so far has signed up more than 200 associa

Written byDavid Fishlock
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

LONDON—Britain is using “ferrets” to transfer technology from its national defense research laboratories into the civil sector. These two-legged ferrets, all of whom have good technical qualifications, are employed by a technology broker to spot promising ideas and obtain licenses for them.

The broker is a private company called Defence Technology Enterprises based at Milton Keynes. Owned by eight British financial institutions, it so far has signed up more than 200 associate members who pay up to $1,600 a year for a “window” on research done for the Ministry of Defense (MoD). Such work constitutes about one-half of the country’s publicly funded R&D.

The ferrets, on the broker’s payroll but operating inside four of the six defense research establishments, stay in close touch with some 4,700 qualified scientists and engineers whose ideas may have commercial value beyond what is being developed for the military.

The venture, which has certain exclusive ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies